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ASpanish male patient with β-thalassaemia major was studied. Compoundheterozygosity was found for one of themost common
β-globingenemutationsintheSpanishpopulation(codon39C → T)andforamutationintheTATAboxelementoftheβ-globin
gene promoter (−28A → C mutation). To our knowledge this is the ﬁrst report of a CD39 C → Ta n d−28A → C change
association and the ﬁrst report of the −28A → C substitution in a Spanish patient.
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1.Introduction
β-thalassaemia is a hereditary and heterogeneous group of
disorders caused by mutations in the β-globin gene that
result in the reduced or nonproduction of β-globin chains.
The inheritance of one mutated allele is usually asymp-
tomatic (β-thalassaemia trait), but the inheritance of two
d e f e c t i v ea l l e l e s( h o m o z y g o t eo rc o m p o u n dh e t e r o z y g o t e )
would produce β-thalassaemia major (BTM) or intermedia
(BTI) [1]. The severity of the symptoms of β-thalassaemia
depends in part on the combination of β-globin gene
mutations. However, predicting clinical phenotype based
on the β-globin genotype is not always straightforward
since there are other genetic factors than can ameliorate or
worsen the β-thalassaemia phenotype [2–6]. Hence, clinical
classiﬁcation is based in the necessity to enroll a particular
patientinaregulartransfusionprogram(BTM)ornot(BTI).
The mutations causing β-thalassaemia can be found in
the β-globin gene exons, in the splice consensus sequences or
in the transcription factor binding sites within the promoter
region, resulting in a reduced eﬃciency of transcription
initiation [1, 7]. Within each population, a small number
of mutations are found. For example, in the Spanish
population, a total of 86.6% of the alleles identiﬁed can be
grouped into only ﬁve diﬀerent mutations [8].
Here we describe a patient of Spanish descent with BTM
(transfusion-dependent) who is compound heterozygous for
one of the most common β-globin gene mutation in Spanish
population (CD39 C→T) [8, 9] and an A to C substitution
at position −28 relative to the transcription start site. This
−28 mutation, ﬁrst described in Kurdish Jew descendents,
aﬀects the TATA box element in the β-globin gene promoter
reducing mRNA amounts [10, 11]. To our knowledge this is
the ﬁrst report of a CD39 C→Ta n d−28 A→C mutations
association and the ﬁrst report of the −28 A→C substitution
in a Spanish patient.
2. MaterialsandPatients
2.1.CaseHistory. ASpanishmalepatientandhisfamilywere
studied. The propositus is 21-year-old and was diagnosed to
have β-thalassaemia major 20 years ago. He is transfusion-
dependenteachthreeweeks,tomaintainahaemoglobincon-
centration([Hb])of10gr/dL.Abloodcountshowedmarked2 Advances in Hematology
Table 1: Oligonucleotide primers used in this work.
Primers 5  → 3  Sequence (5  → 3 )G e n e U s e
BF1 Sense TCCAGGCAGAAACAGTTAGATG β-Globin Ampliﬁcation and Sequencing
BF2 Sense GAAGAGCCAAGGACAGGTAC β-Globin Sequencing
BF3 Sense TGGCTCACCTGGACAACCTC β-Globin Sequencing
BF4 Sense TCAGGGCAATAATGATACAA β-Globin Sequencing
BR1 Antisense ATGCACTGACCTCCCACATTC β-Globin Sequencing
BR2 Antisense CCAGCCTTATCCCAACCATAAA β-Globin Sequencing
BR3 Antisense TCACAGTGCAGCTCACTCAGT β-Globin Sequencing
BR4 Antisense CAACTTCATCCACGTTCACC β-Globin Ampliﬁcation and Sequencing
microcytic hypochromic anaemia with [Hb] 6.5g/dL, mean
corpuscular volume (MCV) of 64fL and mean corpuscular
haemoglobin (MCH) of 20pg. Haemoglobin (Hb) analysis
showed levels of HbA2 of 5.1% and HbF of 1.0%. In 1999
he was cholecystectomized due to an acute cholelithiasis,
and in 2000 he was splenectomized. Actually he has been
diagnosed of hemochromatosis due to iron overload, and
he is in a program of iron chelation with desferrioxamine.
Both parents are Spanish and both showed a thalassaemia
minor phenotype. The mother showed minimal anaemia
([Hb] 11.6g/dL) with slightly hypochromic and microcytic
(MCV 69fL, MCH 21.8pg) and increased HbA2 4.8% and
HbF 1.9%. The father showed milder anaemia with [Hb]
13.4g/dL, MCV 71fL, MCH 23pg, HbA 2 5.6%, and HbF
1.0%.
2.2. DNA Isolation. DNA was extracted from peripheral
EDTA anticoagulated whole blood using the MagNA Pure
LC automated system (Roche Applied Science, Manheim,
Germany) following the manufacturer’s instructions.
2.3. β-Globin Gene Analysis. The propositus and his parents
were studied for the most frequent β-thalassaemia mutations
in the Mediterranean area by procedures based upon real-
time PCR and speciﬁc ﬂuorescent labeled hybridization
probes including: IVSI-II-745 C→G, CD5 (-CT), CD6 (-A),
CD8 (-AA), CD39 C→T, CD37 G →A, IVSI-I G→A, IVSI-
6T→C, and IVSI-110 G→A[ 12, 13]. The full coding, the
5 UTR,andthe3 UTRsequencesofβ-globingene(GenBank
accession no. U01317) were ampliﬁed and sequenced to
discard other mutations. Primers sequences are displayed
in Table 1. The ampliﬁcations were performed in a 25μL
volume, containing 25mM Cl2Mg, 200μMo fe a c hd N T P
(Promega, Madrid, Spain), 2.5U Expand Long Template
PCR System (Roche), 0.6μM each primer, and 100ng DNA.
Ampliﬁcation was performed in a PTC-100 thermal cycler
(MJ Research INC, Madrid, Spain) for one cycle of 10
minutes at 95
◦C and then for 35 cycles of 20 seconds at
95
◦C, 20 seconds at 62
◦C, and 1 minute at 72
◦C,followed
by one ﬁnal cycle similar to the previous one but with
1 0m i n u t e sa t7 2
◦C. The PCR products were analyzed by
electrophoresis.
2.4. DNA Sequencing. PCR products were puriﬁed using
ExoSAP-IT (GE Healthcare, Little Chalfont, UK). The PCR
fragments were sequenced by the BigDye terminator V3.1
Cycle Sequencing ready reaction system (Applied Biosys-
tems,Ca,USA)accordingtothemanufacturer’sinstructions.
Sequencing primers are displayed in Table 1. Sequence
analysis was performed on an ABI Prism 3100-Avant DNA
sequencer (Applied Biosystems).
2.5. Analysis of α-Globin Genes as Secondary Modiﬁers of
the β-Thalassemia Clinical Phenotype. β-thalassemia clinical
manifestations could be alter by concomitant α-thalassemia
or by extra copies of the α-globin genes [6, 14]. In order
to evaluate this fact, the most frequent Mediterranean α-
thalassemia deletions (−α3.7,−α4.2,-- MED) and the presence
of extra copies of the α-globin gene were determined in the
proband and in his parents by PCR-GAP [15].
3. Results and Discussion
We have studied a Spanish patient with a BTM phenotype
due to a compound heterozygous genotype never published
before, a β-globin exon gene mutation (C→T transition at
CD39 position) and a β-globin TATA box mutation (A→C
mutation in the −28 position). The ﬁrst nucleotide substitu-
tion was inherited paternally while the TATA box mutation
was inherited maternally. The CD39 C→T mutation is one
of the most common mutations in Mediterranean countries
causing up to 64% of all the Spanish β-thalassaemias [9].
On the other hand, the −28 A→Cm u t a t i o nh a db e e n
barely described in the scientiﬁc literature. The ﬁrst report
describing this allele was published in 1982 where two
Kurdish Jews siblings with BTM were studied [10]. In a
follow-uppaper, the same group established that the patients
were compound heterozygotes for this TATA box mutation
[11].In1992,Basaketal.[16]studiedthemutationsintheβ-
globingeneinagroupofTurkishpatientsexhibitingBTIand
BTM. In this population the −28 A→Cm u t a t i o nw a sr a r e
but the authors did not establish the genotype (homozygous
or compound heterozygous) or the phenotype linked with
the mutation. In 1996, Perea et al. [17] described a Mexican
mestizo family with BTM due to a −28 A→C mutation and
a CD11 –T frame shift compound heterozygosity. The TATA
box mutation in this family was linked to the same haplotype
as described previously for the Kurdish Jews siblings [11]. In
2005, two molecular epidemiological reports were published
studying Middle East populations where the −28 A→CAdvances in Hematology 3
mutation appears to be a rare allele. Adekile et al. [14]
describedanIraqipatientwhowasacompoundheterozygote
for the −28 A→C and the IVS-II-1 G→A mutations.
This patient showed a BTI phenotype. The mild clinical
manifestation was linked to a −158 C→Tp o l y m o r p h i s m
of the γ-globin gene promoter with elevated Hb F together
with α-gene deletion. In the same year, Darwish et al.
[18] report 1 patient harboring the −28 A→Cm u t a t i o n
in homozygosis out of 148 Palestine β-thalassemia patients
studied. Unfortunately, the phenotype of this patient was
not mentioned. Turning to our patient, the BTM phenotype
is consistent with the clinical manifestation observed in
the other compound heterozygous patients described so
far. Moreover, our patient and his family showed no α-
thalassemia deletions (−α3.7,−α4.2,-- MED), extra copies of α-
globin genes, or HbF elevation. Thus, the propositus BTM
phenotypecouldberelatedstrictlytotheβ-globinmutations
described here.
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